[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"probiotic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:probiotic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,47,80,110,139,161,184,212,236,268,295,319,350,382,412,440],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100639450","developing-precision-microbiota-based-cocktail-modification-therapy-to-delay-the-progression-of-parkinsons-disease-pd---use-preclinical-human-trials-to-confirm-the-impact-of-the-optimal-probiotic-y7-tryptophan-and-branched-chain-amino-acid-cocktail-formula-on-early-stage-pd-patients-100639450",false,"NCT07619560","Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease (PD) - Use Preclinical Human Trials to Confirm the Impact of the Optimal \"Probiotic Y7, Tryptophan and Branched-chain Amino Acid\" Cocktail Formula on Early Stage PD Patients","Developing Precision Microbiota-Based Cocktail Modification Therapy to Delay the Progression of Parkinson's Disease - Use Preclinical Human Trials to Confirm the Impact of the Optimal \"Probiotic Y7, Tryptophan and Branched-chain Amino Acid\" Cocktail Formula on Early Stage Parkinson's Disease Patient","Inclusion Criteria:\n\nSubject Inclusion Criteria:\n\n1. Age between 30-85 years old.\n2. Diagnosed with early-stage Parkinson's disease (Hoehn and Yahr scale stage 1-3).\n3. Brain MRI confirms striatal degeneration in the basal ganglia region, with no history of stroke.\n4. Responds to Parkinson's disease-related medications (e.g., Levodopa).\n5. Free of any major or acute illnesses.\n6. Able to comply with the 12 weeks intervention and required assessments for the study.\n\nExclusion Criteria:\n\n1. Unable to complete interviews or has mobility issues.\n2. Presence of major or acute illness before or during the study.\n3. Co-existing intestinal co-infections, such as CDI, E. coli, Salmonella, Shigella, Campylobacter, plague, or cytomegalovirus.\n4. Allergic to the intervention product.\n5. Pregnant or breastfeeding women.","ALL","30 Years","85 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","Preclinical human trials will be utilized to validate the research direction, followed by clinical trials to assess the impact of a cocktail formula product containing the optimal probiotic Y7 combined metabolites on motor, cognitive, and non-motor functions in early Parkinson's disease patients. The study aims to recruit 120 patients (stage 1-3) and employ a two-arm, randomized controlled trial (RCT) design, dividing subjects into intervention and control groups for a 12 weeks trial period. Commercial development will be contingent upon the clinical trial outcomes, evaluating whether the product offers clinical benefits such as delaying Parkinson's disease progression in motor, cognitive, and non-motor functions. Additionally, a personalized and precise prognosis prediction model for Parkinson's disease will be established. This model will gather comprehensive clinical data, including motor function assessments (functional tests, UPDRS), biochemical markers, questionnaire responses, and genotype data (TPM array), as well as metabolite and microbial data. Through integrated analysis of this biological information using machine learning techniques, a personalized and accurate prognosis prediction model for Parkinson's disease will be developed. This model will predict the disease status of PD patients 12 weeks later, accounting for factors such as cocktail therapy. The results will empower PD patients to understand their individual disease progression and treatment prognosis, enabling them to prepare accordingly. Moreover, this model will aid researchers in identifying patient profiles more likely to benefit from treatment, thereby enhancing the evaluation of the efficacy and applicability of cocktail therapy.",[27,28,29],"Parkinson Disease (PD)","Gut Microbiota","Probiotic",[31,32,33],"Parkinson's Disease","Probiotics","Gut microbiota","RECRUITING","2026-05-24",{"date":37,"type":38},"2026-06-02","ACTUAL",{"date":40,"type":38},"2025-05-20",{"date":42,"type":21},"2027-08-31",{"name":44,"class":45},"Taipei Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100633879","probiotic-intervention-on-the-development-of-allergic-diseases-in-infants-exposed-to-antibiotics-early-in-life-100633879","NCT07532421","Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","A Study on the Impact of Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life","Inclusion Criteria:\n\n* Gestational age from 37 weeks to less than 41 weeks;\n* Birth weight between the 10th and 90th percentiles for gestational age;\n* Breastfed (exclusively breastfed after achieving stable feeding volume, with willingness to maintain exclusive breastfeeding for at least 3 months);\n* Postnatal age within 35 days; Consent to participate in this study.\n\nExclusion Criteria:\n\n* Postnatal Apgar score \\\u003C7;\n* Presence of severe congenital malformations or inherited metabolic diseases;\n* Use of probiotics by the infant or the mother within 2 weeks before enrollment.",true,"1 Day","35 Days",{"count":58,"type":21},400,[24],"Early antibiotic exposure is an important environmental factor that disrupts the establishment of the infant gut microbiota and leads to microbial dysbiosis. Accumulating epidemiological evidence indicates that exposure to antibiotics early in life (including both prenatal and postnatal periods) is significantly associated with an increased risk of allergic diseases in childhood. As live microorganisms, probiotics hold potential as a preventive strategy against allergies due to their ability to stabilize the intestinal barrier and regulate immune balance (e.g., promoting Th1\u002FTh2 balance, inducing regulatory T cells, and increasing sIgA secretion). However, current studies have mostly focused on general or high-risk infant populations. For the specific high-risk subgroup that has already been exposed to antibiotics early in life, high-quality randomized controlled trial evidence is still lacking regarding whether probiotic intervention can effectively reduce the incidence of allergies and whether it exerts its effects by reshaping the gut microbiota and metabolites disrupted by antibiotics.\n\nThis study focuses on breastfed infants who received antibiotics during the early postnatal period (within 30 days after birth) and aims to investigate the effect of a probiotic mixture containing Bifidobacterium longum subsp. infantis R0033, Lactobacillus helveticus R0052, and Bifidobacterium bifidum R0071 on the development of allergic diseases after antibiotic exposure.",[62,63,64,29],"Antibiotic","Allergic Diseases","Infants",[66,67,68,69],"probiotics","infants","early postnatal antibiotic exposure","allergic diseases","NOT_YET_RECRUITING","2026-05-06",{"date":73,"type":38},"2026-05-11",{"date":75,"type":21},"2026-04-17",{"date":77,"type":21},"2027-10-31",{"name":79,"class":45},"Peking University Third Hospital",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":87,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100575180","phase-2-biolosion-combined-standard-neoadjuvant-therapy-to-treat-triple-negative-breast-cancer-100575180","NCT06768931","Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer","A Multicenter, Randomized Controlled Phase II Clinical Study of Standard Neoadjuvant Therapy Combined With Biolosion (Oral Probiotic Compound Preparation) in Triple-negative Breast Cancer","Inclusion Criteria:\n\n1. Women aged 1.18 years and above, diagnosed with triple-negative breast cancer (ER≤10%, PR≤10%, HER-2 negative) by pathology;\n2. Patients must have tumor specimens (formalin-fixed, paraffin-embedded, or fresh pre-treated tumor tissue) available for PD-L1 expression testing;\n3. Researchers assess indications for neoadjuvant chemotherapy, with staging from IIA to IIIC, based on imaging or pathological evaluation of cT1c, N1-3, or cT2\\~cT4, cN0\\~N3, and patients with no distant metastasis as evaluated by imaging;\n4. Patients must not have received chemotherapy or targeted therapy for advanced breast cancer;\n5. ECOG PS: 0-2;\n6. Expected survival of ≥12 weeks;\n7. Major organ function levels must meet the following criteria:\n\n1\\) Hematological examination standards must meet: ANC≥1.5×10\\^9\u002FL, PLT≥75×10\\^9\u002FL, Hb≥90g\u002FL (no blood transfusions or blood products within 14 days, and no use of G-CSF or other hematopoietic growth factors for correction) 2) Biochemical examination must meet the following standards: TBIL\\\u003C1.5×ULN, ALT, AST\\\u003C2.5×ULN, for patients with liver metastasis, ALT, AST may be \\\u003C5×ULN, BUN and Cr≤1×ULN or endogenous creatinine clearance ≥50ml\u002Fmin (Cockcroft-Gault formula); 8. Women of childbearing age must have taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within 7 days prior to enrollment, with a negative result, and must be willing to use appropriate contraceptive methods during the trial and for 8 weeks after the last administration of the investigational drug.\n\n9\\. Participants voluntarily join this study, demonstrate good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n1. There is a clear distant transfer;\n2. A history of autoimmune diseases;\n3. Acute or chronic active hepatitis B (defined as positive hepatitis B surface antigen and\u002For hepatitis B core antibody, with hepatitis B virus DNA copy number ≥1×10³ copies\u002Fml or ≥200 IU\u002Fml) or positive antibodies for acute or chronic active hepatitis C, with positive hepatitis C antibodies but negative RNA testing allowed for enrollment.\n4. Previous treatment with immune checkpoint inhibitors;\n5. Received systemic immunostimulants, systemic corticosteroids, or immunosuppressants within the last 4 weeks;\n6. Any severe underlying disease, comorbidities, and active infections, or patients with severe metabolic disorders;\n7. Currently receiving other antitumor treatments;\n8. Known comorbidities (e.g., chronic diarrhea, inflammatory bowel disease, etc.) that, in the investigator's assessment, would increase the risk associated with the administration of the study drug or interfere with the interpretation of study results.\n9. Currently using or planning to use probiotics, yogurt, or bacterial-enhanced foods during the treatment period.\n10. A history of epilepsy or seizure-inducing states;\n11. Pregnant or breastfeeding patients;\n12. Poor compliance or inability to undergo normal follow-up;\n13. Individuals allergic to the study drug;\n14. Diagnosis of other malignancies within the past 5 years, with the exception of: surgically removed non-melanoma skin cancer, adequately treated cervical carcinoma in situ, locally curative prostate cancer, surgically treated ductal carcinoma in situ, or malignancies diagnosed 2 years prior to randomization without evidence of disease and untreated for ≤2 years;\n15. The investigator's judgment on other conditions that may affect the conduct of the clinical study and the determination of study results.","FEMALE","18 Years",{"count":90,"type":21},192,[92],"PHASE2","To evaluate the efficacy and safety of compound preparation Biolosion in combination with standard neoadjuvant therapy for locally advanced triple-negative breast cancer",[95,96,97,98,29],"Breast Cancer","Triple Negative Breast Cancer (TNBC)","Early Stage Breast Cancer","Immunotherapy",[100,32,98],"Triple negative breast cancer","2026-03-26",{"date":103,"type":38},"2026-04-01",{"date":103,"type":21},{"date":106,"type":21},"2035-02-08",{"name":108,"class":45},"Sun Yat-sen University",5,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":54,"sex":16,"minAge":117,"maxAge":88,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":46},"100629584","clinical-trial-of-lactiplantibacillus-plantarum-dad-13-on-gut-microbiota-profile-and-performance-in-adolescent-athletes-100629584","NCT07476573","Clinical Trial of Lactiplantibacillus Plantarum Dad-13 on Gut Microbiota Profile and Performance in Adolescent Athletes","Dad-13","Inclusion Criteria:\n\n* Residing in the BPPLOP dormitory of Central Java Province;\n* Having a normal body mass index;\n* Being an athlete in an endurance sport;\n* Having no growth disorders\n\nExclusion Criteria:\n\n* Injury, any health contraindication or failure to perform exercise procedures;\n* Gastrointestinal infections, diseases, disorders;\n* Past history of gastrointestinal surgery;\n* Failure to follow the study protocol;\n* Declared general feeling of being unwell","12 Years",{"count":119,"type":21},30,[24],"The aim of this research is to analyze the effect of a Lactiplantibacillus plantarum Dad-13 supplementation on the gut microbiota profile and performance of adolescent athletes.",[123,29,124,28],"Athlete","Performance",[126,127,128,129],"athlete","probiotic","performance","gut microbiota","2026-03-19",{"date":132,"type":38},"2026-03-23",{"date":134,"type":21},"2026-04-13",{"date":136,"type":21},"2026-08-30",{"name":138,"class":45},"Gadjah Mada University",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":145,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":156,"leadSponsor":158,"locationsCount":46},"100625674","probiotics-antibiotics-and-the-post-antibiotic-microbiota-100625674","NCT07425704","Probiotics, Antibiotics and the Post-Antibiotic Microbiota","Inclusion Criteria:\n\n1. Adults, aged 18-40.\n2. Been prescribed an oral dose of cephalosporin antibiotic lasting 5 - 10 days.\n3. Willing to provide stool samples and, for women, vaginal samples.\n4. Willing to avoid consumption of any other probiotic capsules\u002Ftablets during the study.\n\nExclusion Criteria:\n\n1. If antibiotics prescribed are intended to treat any gastrointestinal or vaginally related issue.\n2. Any antibiotic intake within the last 3 months.\n3. Immunodeficient or undergoing immunosuppressive therapy.\n4. Currently diagnosed with diabetes\u002Fcardiovascular disease\u002Fcancer\u002Fdementia.\n5. Any unexplained loss of weight in recent months.\n6. Known to be pregnant or \\\u003C3 months postpartum.","40 Years",{"count":147,"type":21},50,[24],"Antibiotic therapy can cause gastrointestinal dysbiosis and this study will assess the impact of probiotic supplementation on microbiological composition and functionality pre- and post- antibiotic therapy",[29,151],"Microbiome","2026-03-16",{"date":154,"type":38},"2026-03-18",{"date":134,"type":21},{"date":157,"type":21},"2026-12-01",{"name":159,"class":160},"Cultech Ltd","INDUSTRY",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":46},"100620629","efficacy-of-symprove-probiotics-in-coeliac-disease-100620629","NCT07360106","Efficacy of Symprove Probiotics in Coeliac Disease","A Proof-of-Concept Study to Assess the Efficacy of Symprove Probiotics in Managing Persistent Gastrointestinal Symptoms in Adult Coeliac Disease Patients in Histological Remission","Inclusion Criteria:\n\nAdults aged 18-65 years with biopsy-confirmed coeliac disease (CD)\n\nNormal duodenal biopsy (Marsh 0 or Marsh I) within the last 12 months, confirming histological remission\n\nAdherence to a strict gluten-free diet (GFD) for at least 6 months\n\nPersistent gastrointestinal (GI) symptoms for at least 6 months despite adherence to GFD and histological remission\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\nActive gluten ingestion or non-adherence to a gluten-free diet\n\nUse of antibiotics within the past 3 months\n\nUse of probiotics within the past 3 months\n\nKnown comorbidities affecting gastrointestinal function (e.g., Crohn's disease, ulcerative colitis, irritable bowel syndrome with severe diarrhea, or other significant gastrointestinal disorders)\n\nPregnancy or lactation\n\nInability to provide informed consent","65 Years",{"count":170,"type":21},24,[24],"Coeliac Disease (CD) is a lifelong autoimmune condition where eating gluten (a protein found in wheat, barley, and rye) causes damage to the small intestine. It affects around 1 in 100 people. Most individuals feel better and their gut heals after switching to a strict gluten-free diet. However, up to 1 in 5 people with coeliac disease continue to experience unpleasant gut symptoms-such as bloating, pain, and diarrhoea-despite following the diet and having a healed intestine. These ongoing symptoms can be very distressing and impact daily life.\n\nThis study investigates whether a food supplement called Symprove, a probiotic drink containing live good bacteria, can help relieve these ongoing symptoms. Scientists believe that in some people with coeliac disease, the community of bacteria in the gut (called the microbiota) becomes unbalanced, even after going gluten-free. This imbalance (known as dysbiosis) may lead to inflammation, irritation, and symptoms similar to irritable bowel syndrome (IBS).\n\nThe aim of this study is to test whether Symprove can help correct this imbalance and reduce symptoms. Participants will take Symprove daily and their symptoms, quality of life, and gut bacteria (measured from stool samples) will be monitored over time.\n\nThe study hopes to answer three key questions: Can Symprove reduce gut symptoms in people with coeliac disease who are in remission? Does it work by restoring a healthy balance of gut bacteria? Are people with more severe imbalance (dysbiosis) more likely to have symptoms?\n\nIf successful, this research could offer a safe, non-drug option to improve life for coeliac patients who continue to suffer symptoms despite avoiding gluten. It could also help suggest that gut bacteria play a role in ongoing symptoms and are a target for future treatment.",[174,29,175],"Coeliac Disease","Gluten",{"date":177,"type":38},"2026-03-17",{"date":179,"type":38},"2026-01-29",{"date":181,"type":21},"2026-12",{"name":183,"class":45},"Sheffield Teaching Hospitals NHS Foundation Trust",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":191,"maxAge":117,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":46},"100620380","probiotic-based-versus-ethyl-lauroyl-arginate-containing-mouthwashes-on-streptococcus-mutans-counts-dental-plaque-accumulation-and-salivary-ph-in-a-group-of-egyptian-school-children-100620380","NCT07356869","Probiotic-Based Versus Ethyl Lauroyl Arginate-Containing Mouthwashes on Streptococcus Mutans Counts, Dental Plaque Accumulation, and Salivary pH in a Group of Egyptian School Children","Comparative Evaluation of Probiotic-Based Versus Ethyl Lauroyl Arginate-Containing Mouthwashes on Streptococcus Mutans Counts, Dental Plaque Accumulation, and Salivary pH in a Group of Egyptian School Children: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Healthy Egyptian schoolchildren aged 6-12 years.\n* Good general health.\n* Mild to moderate dental plaque accumulation.\n* Parental\u002Fcaregiver willingness to provide consent\n\nExclusion Criteria:\n\n* Antibiotic or antimicrobial use within the last month.\n* Allergies to the mouthwash components.\n* Systemic diseases affecting oral health.\n* Orthodontic appliances or extensive dental restorations.","6 Years",{"count":193,"type":21},66,[24],"This study aims to compare the efficacy of probiotic-based mouthwashes versus ethyl lauroyl arginate-containing mouthwashes in reducing Streptococcus mutans count, dental plaque accumulation, and salivary pH among a group of Egyptian schoolchildren.",[29,197,198,199,200,201,202],"Ethyl Lauroyl Arginate","Mouthwashes","Streptococcus Mutans","Dental Plaque","Salivary pH","Children","2026-01-13",{"date":205,"type":38},"2026-01-21",{"date":207,"type":38},"2025-08-15",{"date":209,"type":21},"2026-09-01",{"name":211,"class":45},"Al-Azhar University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":46},"100614151","multi-strain-probiotic-effects-on-self-reported-constipation-100614151","NCT07275866","Multi-strain Probiotic Effects on Self-Reported Constipation","A Pilot Study of a Multi-Strain Liquid Probiotic in Individuals Self-reporting Constipation in the General Population.","Inclusion Criteria:\n\n1. Participant has provided written informed consent before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.\n2. Participant has Cleveland Clinic constipation score (CCCS) of 9-16 at screening call\n3. Participant is willing to discontinue all other therapies for constipation and undergo washout where applicable.\n4. Participant is a male or non-pregnant female and is 18-70 years of age\n5. If WOCBP participant is willing to adhere to one of the following methods of contraception:\n\n   i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) vi) Sexual abstinence (if it is in line with participants' preferred and usual lifestyle).\n\n   or has had a: v) Hysterectomy or has a: vi) Vasectomised partner\n6. Participant can communicate well with the Investigator and to comply with the requirements for the entire study.\n7. Participant has capacity to understand written English.\n8. Participant has a body mass index (BMI) of 18.5 - 39.9kg\u002Fm2 (bounds included).\n9. Participant agrees to follow all pre-test preparation for the ATMO capsule transit study.\n\nExclusion Criteria:\n\n1. Women who are pregnant and\u002For breastfeeding.\n2. Participants who are planning to significantly change their diet (e.g. weight loss program, becoming vegetarian) during the study period.\n3. Participant has had diarrhoea within 7 weeks of screening period.\n4. Prior abdominal surgery involving resection of the small or large bowel.\n5. Prior bariatric surgery involving resection of the stomach or by-pass procedures.\n6. Type 1 diabetes mellitus.\n7. Known organic or structural GI disease including:\n\n   * Coeliac disease\n   * Inflammatory bowel disease\n   * Diverticulitis\n   * Small bowel strictures\n8. Irritable bowel syndrome where the predominant symptom is pain (assessed via screening questions).\n9. Oropharyngeal dysphagia or difficulty swallowing capsules.\n10. Any other medical condition that the investigator deems may confound results or affect participants' safety in the study.\n11. Any use of prohibited medication that the participant cannot complete appropriate washout for.\n12. Insufficient knowledge of English to complete the daily bowel diary.\n13. Allergy to any component of the supplement, motility bar, lactulose or Zoe blue cookie.\n14. Participant is involved in this study as an investigator, sub-Investigator, study coordinator, other study staff, or Sponsor member.\n15. Previous use of the probiotic Symprove.","70 Years",{"count":221,"type":21},20,[24],"Constipation is a prevalent gastrointestinal condition. Beyond simple lifestyle measures (e.g. increasing fibre intake, hydration, levels of exercise), medical therapies are available for management. However, a sizeable number of sufferers are dissatisfied with drug treatments (either over-the-counter or prescribed), meaning there is an unmet need for alternative therapeutic strategies.\n\nPre, pro- and synbiotics have emerged as one alternative treatment, and a growing body of evidence now supports their use in a proportion of individuals with mild constipation. However, it is currently not possible to predict which individuals may benefit. A better understanding of an individuals' symptoms and underlying pathophysiology may allow for more targeted treatment.\n\nThe multistrain live bacterial food product (probiotic) being tested contains billions of live and active bacteria that has been shown to improve symptoms in the irritable bowel syndrome (IBS: which is 'constipation-predominant' in many). Notably, improvements ('completely resolved' or 'some positive difference') in bowel habit satisfaction, abdominal pain, bloating and urgency, as well as on quality of life have been shown after 4 or more weeks of this probiotc.\n\nThis study aims to have 20 participants with self-reported constipation to assess improvements in constipation symptoms, quality of life and measures of gut function.",[225,29,226],"Constipation","Probiotic Intervention","2025-12-10",{"date":229,"type":38},"2025-12-18",{"date":231,"type":38},"2025-10-03",{"date":233,"type":21},"2026-04",{"name":235,"class":45},"Dr Anthony Hobson",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":54,"sex":16,"minAge":244,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":256,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":4},"100595529","probiotics-and-active-aging-enhancing-gut-health-100595529","NCT07033637","Probiotics and Active Aging: Enhancing Gut Health","Promoting Health Through Symbiosis: Exploring the Relationship Between Gut Microbiota, Probiotics, and Physical Activity in Older Adults","PAAEGH","Inclusion Criteria:\n\n* Adults aged 60 years or older.\n* Residents of Castilla-La Mancha or Madrid.\n* Able to provide informed consent.\n* For the intervention group: enrolled in a municipal physical activity program with a minimum frequency of 2 sessions per week.\n* Willing to participate in all assessments and follow study instructions.\n* Consent: Participants must provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Recent serious musculoskeletal injuries (e.g., muscle tears, ligament ruptures, fractures).\n* Current symptoms during exercise such as chest pain, dizziness, or joint pain.\n* Uncontrolled hypertension (≥160\u002F100 mmHg).\n* Recent cardiac failure or infectious disease (e.g., meningitis, hepatitis, flu).\n* Chronic gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis, IBS).\n* Regular use of medications affecting gut motility or microbiota (e.g., laxatives \\>3 times\u002Fweek).\n* Immunodeficiency (e.g., HIV, active cancer).\n* Use of antibiotics (oral or parenteral) within 4 weeks prior to the study.\n* Regular intake of probiotic supplements or foods (e.g., Actimel) within 2 weeks prior to the study.","60 Years",{"count":246,"type":21},90,[24],"The general objective of this clinical trial is to assess the physical fitness and gut microbiota of older adults, thereby highlighting the importance of focusing on health maintenance. By making use of available resources and fostering collaboration among the elements involved in the study, more specific objectives can be defined:\n\n1. To determine the state of the gut flora in older adults through the analysis of the intestinal microbiota.\n2. To identify changes in the intestinal microbiota resulting from the intake of probiotics in older adults.\n3. To evaluate the effects of the intestinal microbiota in older adults participating in a training programme.\n4. To assess the physical fitness and perceived quality of life in older adults who engage in sport activities supported by technology.\n\nParticipants will:\n\n* Perform physical tests such as the 6-Minute Walk Test (6MWT), the Timed Up and Go (TUG), and the Sit-to-Stand test.\n* Complete wellbeing questionnaires to assess their perceived quality of life and health status.\n* Complete dietary habit questionnaires.\n* Provide stool samples for microbiota analysis.\n* Take part in exercise interventions or placebo exercise sessions, depending on their assigned group.",[250,251,252,253,254,29,255],"Gut -Microbiota","Older People","Physical Activity","Physical Fitness","Mental Health","Healthy",[257,129,258],"older people","physical activity","2025-06-13",{"date":261,"type":38},"2025-06-24",{"date":263,"type":21},"2025-09-01",{"date":265,"type":21},"2026-06-30",{"name":267,"class":45},"Jose Luis Felipe",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":54,"sex":16,"minAge":88,"maxAge":219,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":277,"conditions":278,"keywords":284,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":46},"100589896","phase-1-efficacy-of-repeated-transcranial-magnetic-stimulation-combined-with-a-live-probiotic-tablet-combined-bifidobacterium-lactobacillus-enterococcus-and-bacillus-cereus-tablets-live-in-diarrhea-predominant-irritable-bowel-syndrome-ibs-d-100589896","NCT06960369","Efficacy of Repeated Transcranial Magnetic Stimulation Combined With a Live Probiotic Tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)","Inclusion Criteria:\n\n1. Must meet the diagnostic criteria for Irritable Bowel Syndrome of Rome IV.\n2. Age range between 18-70 years.\n3. The duration of the disease is more than 6 months.\n4. There are no pathologic abnormalities or biochemical changes that could explain the bowel-related symptoms.\n5. The IBS symptom severity score at baseline must not be less than 75.\n6. No pharmacological treatment (excluding emergency treatment) for IBS for at least 2 weeks prior to the start of treatment; no concurrent participation in other clinical programs.\n7. Voluntarily sign the relevant informed consent form and voluntarily participate in this clinical project.\n\nExclusion Criteria:\n\n1. Be less than 18 years old or more than 70 years old.\n2. Those who suffer from severe liver, kidney, hematopoietic system diseases, cardiovascular and cerebrovascular diseases, and psychiatric diseases that significantly affect cognitive function.\n3. Patients with clear organic diseases of the intestinal tract; patients with diabetes, hyperthyroidism and other systemic diseases that affect the digestive tract dynamics; patients who have had a history of surgery on the anus and intestines or the abdomen.\n4. The presence of the following conditions affecting the efficacy or safety judgment: ① regular use of preparations and drugs affecting gastrointestinal dynamics or function; ② treatment with other treatments and drugs that may affect the results of the judgment.\n5. Those who are pregnant, breastfeeding or less than 12 months after delivery.\n6. Patients with severe fear of needles, metal allergies or sensitivities, or those with pacemakers.\n7. Patients who do not comply with the randomized assignment to the treatment group or have a tendency to be unstable such as poor compliance.\n8. Patients who are participating in other research projects.\n9. Those who do not want to sign the informed consent form.",{"count":58,"type":21},[276],"PHASE1","To evaluate the overall efficacy of repeated Transcranial Magnetic Stimulation(rTMS) combined with a Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)\n\nMethods:\n\nClinical efficacy evaluation of TMS combined with Live Probiotic tablet for chronic diarrhea in IBS patients. The 400 IBS patients who meet the recruitment criteria for the clinical study will be randomized into 100 patients in rTMS combined with Live Probiotic tablet (Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live), rTMS combined placebo, shamrTMS combined with Live Probiotic tablet(Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus Tablets, Live) and shamrTMS combined placebo group. Corresponding treatment was given for 2 week, rTMS group received 1 Hz\u002Fs, 20 min for 2 week; Live Probiotic tablet group received tablets orally, 150 mg three times a day for 2 week, shamrTMS group received 0 Hz\u002Fs, 20 min for 2 week; placebo group received tablets orally, 150 mg three times a day for 2 week. Clinical assessment included symptoms, stool traits, mood, and sleep.\n\n2\\. Study on the mechanism of using intestinal flora data to evaluate the treatment of chronic diarrhea in IBS patients. 30 cases each were included in the 4 groups of IBS-eligible patients, and repeated transcranial magnetic stimulation treatment was given to the patient group for 2 week, and the patient group underwent the assessment of investigating the quantity and metabolic changes of the intestinal flora in feces before and after the treatment.",[279,280,281,29,282,283],"Irritable Bowel Syndrome","Irritable Bowel Syndrome With Diarrhea (IBS-D)","Repetitive Transcranial Magnetic Stimulation (rTMS)","Chronic Diarrhea","Intestinal Flora",[285,281,29],"Irritable Bowel Syndrome with diarrhea (IBS-D)","2025-05-05",{"date":288,"type":38},"2025-05-07",{"date":290,"type":38},"2024-12-01",{"date":292,"type":21},"2026-06-01",{"name":294,"class":45},"The First Affiliated Hospital of Soochow University",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":16,"minAge":302,"maxAge":303,"enrollmentInfo":304,"targetDuration":303,"studyType":306,"phases":4,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100584177","probiotics-for-preterm-infants-100584177","NCT06885944","Probiotics for Preterm Infants","Probiotics for Preterm Infants After Full Enteral Feeding","Inclusion Criteria: \\\u003C32 weeks, \\\u003C1500 g birthweight -\n\nExclusion Criteria: Congential anomalies, still parenteral feeding, BW\\\u003C800 gr and \\\u003C23 weeks of GA\n\n\\-","7 Days","3 Months",{"count":305,"type":21},100,"OBSERVATIONAL","Probiotics will be used for preterm infants under 32 weeks of gestation and under 1500 g birthweight. Our aim was to investigate the effects of probiotics for stable preterm infants after extubation and who reached full enteral feeding. There are some hesitations among care-givers to start probiotics early due to safety issues although there are many positive effects of these products reported int the literature.",[309,29],"Preterm Infant Feeding Outcomes","2025-03-13",{"date":312,"type":38},"2025-03-20",{"date":314,"type":21},"2025-03-30",{"date":316,"type":21},"2025-11-30",{"name":318,"class":45},"Ankara City Hospital Bilkent",{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":16,"minAge":326,"maxAge":88,"enrollmentInfo":327,"targetDuration":4,"studyType":22,"phases":329,"briefSummary":330,"conditions":331,"keywords":337,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":4},"100577070","phase-1-efficacy-and-safety-of-oral-probiotics-on-ocular-symptoms-and-gut-microbiome-of-children-with-vernal-keratoconjunctivitis-100577070","NCT06793514","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis","Efficacy and Safety of Oral Probiotics on Ocular Symptoms and Gut Microbiome of Children with Vernal Keratoconjunctivitis: a Double-blind Clinical Trial Study","Inclusion Criteria:1- Patients whose diagnosis of vernal keratoconjunctivitis is confirmed based on clinical criteria. 2-Patients with an age range of 4 to 18 years. 3-Patients who have not received drug treatment for vernal keratoconjunctivitis disease recently.\n\n\\-\n\nExclusion Criteria:1-Having other eye diseases (except refractive error) 2-Change in the diagnosis of the disease during the study 3-Antibiotics, anti-inflammatory drugs, immunosuppressive drugs 4-History of known gastrointestinal diseases (such as IBD, Celiac,...) 5- History of digestive problems in the last two weeks 6- Lack of consent to participate in the study 7- Having an eye infection in the last one month 8- People who were athletes or involved in intense physical activity 9- Smoking, alcohol and drugs. 10- Using drugs that affect appetite, bowel movements, and nutrient absorption 11- Using prebiotics, probiotics or synbiotics in the last 3 months 12- People who have been on a diet to lose or gain weight in the last 3 months 13- People who have undergone gastrointestinal surgery. 14- Changing the patient's diagnosis in the course of treatment 15- Failure to follow up the patient at the specified times for the visit and assessment of the patient's bed 16- Taking fat-reducing drugs 17-Oral hypoglycemic drugs, insulin, antihypertensive drugs-18- Diuretics, laxatives, antacids 19-Food supplements in the last 3 months.\n\n\\-","4 Years",{"count":328,"type":21},32,[276],"The primary goal of this study is to determine the effects of oral probiotics on the severity of ocular symptoms and the alterations of the gut microbiome of children (4-18 years old) with vernal keratoconjunctivitis. The current study will also assess the safety of oral probiotics among children with vernal keratoconjunctivitis. The main questions it aims to answer: 1- Does treatment with oral probiotics improve the severity of ocular symptoms in children with vernal keratoconjunctivitis? 2- Does treatment with oral probiotics alter the gut microbiome of children with vernal keratoconjunctivitis? Researchers will compare the ocular symptoms and gut microbiome between two groups receiving oral probiotics and placebo among children with vernal keratoconjunctivitis.\n\nParticipants The participants will receive the oral probiotics and placebo ever day for one month.\n\nRecord their regimen and keep a diary of their symptoms.",[29,332,333,334,335,336],"Ocular Surface Disease","Ocular Diseases","Ocular Dryness","Gut Microbiome Dysbiosis","Gut -microbiota",[29,338,339,340],"Vernal keratoconjunctivitis","Clinical trial","gut microbiome","2025-01-21",{"date":343,"type":38},"2025-01-27",{"date":345,"type":21},"2025-02-01",{"date":347,"type":21},"2025-06-01",{"name":349,"class":45},"Mohsen Pourazizi",{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":16,"minAge":88,"maxAge":168,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":361,"conditions":362,"keywords":366,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":377,"leadSponsor":379,"locationsCount":381},"100576953","phase-4-impact-of-probiotics-on-gut-microbiome-during-antibiotic-prophylaxis-in-elective-orthopedic-surgery-100576953","NCT06791993","Impact of Probiotics on Gut Microbiome During Antibiotic Prophylaxis in Elective Orthopedic Surgery","Impact of Probiotics Combined with Antibiotic Prophylaxis on Gut Microbiome Balance in Patients Undergoing Elective Orthopedic Surgery, Double-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged between 18 and 65 years\n* Scheduled for elective low-risk orthopedic surgery (carpal tunnel release, A1 pulley release, knee arthroscopic surgery).\n\nExclusion Criteria:\n\n* History of infection or antibiotic use within the last 12 weeks.\n* Use of routine probiotics, vitamins, or herbal supplements in the last 4 weeks.\n* Known allergy to beta-lactam or cephalosporin antibiotics.\n* History of autoimmune disease, uncontrolled systemic disease, or chronic inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis).\n* History of chronic intestinal diseases such as small intestine bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or celiac disease.\n* Increased risk of infection due to medical comorbidities or use of immunosuppressive drugs.",{"count":358,"type":21},60,[360],"PHASE4","This study aims to evaluate whether probiotics can help maintain a healthy gut microbiome in patients receiving prophylactic antibiotics during elective orthopedic surgery. Antibiotics, while effective in preventing infections, can disrupt the balance of gut bacteria, leading to dysbiosis. The study hypothesizes that the use of probiotics during the perioperative period can prevent or reduce this disruption, supporting gut health and overall well-being. The research seeks to answer whether combining probiotics with routine antibiotic prophylaxis can preserve gut microbiome balance and improve patient outcomes.",[363,336,364,29,365],"Dysbiosis","Microbiome Analysis","Antibiotic Prophylaxis",[367,368,369,32,365,370,371,372],"Gut Microbiome","Intestinal Dysbiosis","Surgical Site Infection","Human Milk Oligosaccharides (HMO)","Shotgun Metagenomic Sequencing","Short-Chain Fatty Acids (SCFAs)","2025-01-18",{"date":375,"type":38},"2025-01-24",{"date":345,"type":21},{"date":378,"type":21},"2025-10-01",{"name":380,"class":45},"Acibadem Maslak Hospital",6,{"id":383,"slug":384,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":16,"minAge":389,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":398,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":46},"100476453","lactobacillus-reuteri-strain-combination-in-children-treated-with-ppi-100476453","NCT05484128","Lactobacillus Reuteri Strain Combination in Children Treated With PPI","Lactobacillus Reuteri Strain Combination (Strains DSM 17938 and ATCC PTA 6475) in Children Treated With Proton Pump Inhibitors","Inclusion Criteria:\n\n* Age: children between 1 month and 14 years of age;\n\n  o We start with children older than 4 years of age.\n* Necessity of therapy with Proton Pump Inhibitors for Gastroesophageal reflux disease and\u002For Functional Dyspepsia;\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Neurological pathologies (PCI and Spastic tetra-paresis);\n* Nasogastric feeding;\n* Known immunodeficiency;\n* Previous therapy with gastric acid inhibitors;\n* HP infection;\n* Assumption of prebiotics, other probiotics or symbiotics in the previous month;\n* Malnutrition or severe dystrophy;\n* Cystic Fibrosis.","12 Months","14 Years",{"count":392,"type":21},172,[24],"Probiotics might be of help in preventing dysbiosis and emergence of SIBO. Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475; the first have extensive data supporting its use in gastric infections (18) however, it lacks the anti-inflammatory properties that have been provided by L. Reuteri DSM ATCC PTA 6475 that has excellent acid resistance and has strong anti-inflammatory properties (19); for these reasons, Gastrus is the best candidate for this indication.",[396,397,29],"Gastric Lesion","Proton Pump Inhibitor Adverse Reaction",[399,400,401,402],"Reuteri","Proton Pump Inhibitor","gastrus","infections","2024-12-03",{"date":405,"type":38},"2024-12-05",{"date":407,"type":38},"2020-03-04",{"date":409,"type":21},"2025-12-31",{"name":411,"class":45},"University of Bari",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":54,"sex":16,"minAge":145,"maxAge":18,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":428,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":46},"100570694","phase-4-multimodal-image-technologies-investigate-the-role-and-mechanism-of-probiotics-in-improving-rbd-with-parkinsons-disease-100570694","NCT06710574","Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease","Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving Rapid Eye Movement Behavior Disorder with Parkinson's Disease","Inclusion Criteria:\n\nInclusion criteria for PD-RBD patients:\n\n* Age between 40 and 80 years, both males and females\n* Patients with idiopathic Parkinson's disease, meeting the MDS clinical diagnostic criteria for Parkinson's disease (2015)\n* Modified Hoehn and Yahr stage of Parkinson's disease ≤ stage 3\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* Rapid Eye Movement Sleep Behavior Disorder (RBD) screening questionnaire score \\> 5, diagnosed with RBD based on polysomnography results, and exclusion of obstructive sleep apnea\n* Stable condition of Parkinson's disease motor symptoms and RBD symptoms in the month prior to enrollment, with no adjustments to Parkinson's disease medications in the month prior to enrollment\n* Discontinuation of benzodiazepines such as clonazepam and melatonin in the month prior to enrollment\n* No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nInclusion criteria for iRBD patients:\n\n* Age between 40 and 80 years, both males and females\n* Rapid Eye Movement Sleep Behavior Disorder (RBD) screening questionnaire score \\> 5, diagnosed with RBD based on polysomnography results, and exclusion of obstructive sleep apnea or restless legs syndrome\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* Discontinuation of benzodiazepines such as clonazepam and melatonin in the month prior to enrollment\n* No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nInclusion criteria for healthy subjects\n\n* Age between 40 and 80 years, age and gender matched with the above two groups of patients\n* Rapid Eye Movement Sleep Behavior Disorder screening questionnaire score ≤ 5, exclusion of RBD or obstructive sleep apnea based on polysomnography results\n* No dementia, with a Mini-Mental State Examination (MMSE) score \\> 24.\n* No depression or anxiety, as indicated by Hamilton Depression Scale score \\\u003C 9 and Anxiety Scale score \\\u003C 14\n* No severe constipation, not meeting the diagnostic criteria for Rome III chronic constipation; No use of probiotics, prebiotics (including lactulose), or antibiotics for the two months prior to enrollment, if used, a two-month washout period should be observed\n* Understanding and willingness to comply with the study protocol, agreeing to participate, and signing the informed consent form.\n\nExclusion Criteria:\n\nPD-RBD exclusion criteria:\n\n* Parkinsonism plus syndrome and secondary parkinsonism such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary parkinsonism\n* Taking any probiotics or prebiotics (including lactulose) or antibiotics within 2 months before enrollment\n* Adjustment of Parkinson's disease medication within 1 month before enrollment; In group 1 month before taking clonazepam and benzodiazepines medicine melatonin, etc.\n* With the following diseases such as Alzheimer's disease, malignant tumor, spinal cord lesions, epilepsy, autonomic nerve disease (urinary retention, urinary incontinence or orthostatic hypotension, vertical drop in blood pressure in five minutes more than 30\u002F15 MMHG), etc.; New onset of cerebrovascular disease or severe sequelae of cerebrovascular disease within 3 months, affecting the assessment\n* Patients with anxiety or depression and taking medication\n* Serious cardiovascular diseases (such as the American heart association heart function class for Ⅲ - Ⅳ of congestive heart failure, the 6 month history of myocardial infarction, etc.)\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; Serum creatinine is higher than the upper limit of normal value 1. 5 times\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG;\n* Known to be allergic to Bifidobacterium triple viable capsules, Bacillus licheniformis, or their excipients\n* Has a history of history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment\n* Refusal to participate in the study or inability to cooperate with the study investigator; The researchers judgment for doesn't fit into the group of patients.\n\nExclusion criteria for iRBD:\n\n* PD motor symptoms and parkinsonism were included in the PD-RBD group; \"Parkinsonism plus syndrome and secondary parkinsonism, such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary Parkinson's disease;\"\n* Into the group 2 months before taking any probiotics and prebiotics (including lactulose) or antibiotics\n* Adjustment of Parkinson's disease medication within 1 month before enrollment; In group 1 month before taking clonazepam and benzodiazepines medicine melatonin, etc.\n* With the following diseases, including but not limited to obstructive sleep apnea syndrome, Alzheimer disease, malignant tumor, spinal cord lesions, epilepsy, autonomic nerve disease (urinary retention, urinary incontinence or orthostatic hypotension, vertical drop in blood pressure in five minutes more than 30\u002F15 MMHG), etc.; 3 month new cerebrovascular disease or severe cerebrovascular disease sequela, impact assessment;\n* Patients with severe anxiety or depression or under drug treatment;\n* Severe cardiovascular diseases (such as congestive heart failure with American Heart Association functional class Ⅲ-Ⅳ, history of myocardial infarction within 6 months, etc.);\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; The serum creatinine was higher than the upper limit of the normal range. 5 times;\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG;\n* Known to be allergic to Bifidobacterium triple viable capsules, Bacillus licheniformis, or their excipients;\n* With a history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment;\n* Refused into groups, and can cooperate with researchers; Patients who were judged by the investigator to be ineligible for enrollment.\n\nHealthy subjects exclusion criteria:\n\n* Patients with Parkinson's disease motor symptoms and met the diagnosis of parkinsonism were included in PD-RBD group; \"Parkinsonism plus syndrome and secondary parkinsonism, such as multiple system atrophy, progressive supranuclear palsy, cortical basal ganglia degeneration, dementia with Lewy bodies, vascular parkinsonism, post-encephalitis parkinsonism, or any other non-primary Parkinson's disease;\" 2) taking any probiotics or prebiotics (including lactulose) or antibiotics within 2 months before enrollment; 1 month before the 3) into the group of Parkinson's disease medication adjustment; Benzodiazepines such as clonazepam and melatonin were taken within 1 month before enrollment. 4) combined with the following diseases, including but not limited to obstructive sleep apnea syndrome, Alzheimer's disease, malignant tumors, spinal cord lesions, epilepsy, autonomic disorders (urinary retention, urinary incontinence or orthostatic hypotension, blood pressure drop more than 30\u002F15 MMHG after 5 minutes of standing), etc.; New onset of cerebrovascular disease or severe sequelae of cerebrovascular disease within 3 months, affecting the assessment\n* Patients with severe anxiety or depression or under drug treatment;\n* Severe cardiovascular diseases (such as congestive heart failure with American Heart Association functional class Ⅲ-Ⅳ, history of myocardial infarction within 6 months, etc.)\n* Severe liver and kidney dysfunction, cereal third transaminase, aspertate aminotransferase, total bilirubin is higher than the upper limit of normal value of 1. 5 times; The serum creatinine was higher than the upper limit of the normal range. 5 times\n* Pregnant and lactating women or pregnant women aged 40-60 years with positive HCG; 9) known to the bifidobacterium triple viable capsules, bacillus licheniformis, or its accessories, and other allergies;\n* With a history of drug abuse or alcohol dependence\n* Were enrolled in another clinical trial at enrollment;\n* Refused into groups, and can cooperate with researchers; The researchers judgment for doesn't fit into the group of patients.",{"count":20,"type":21},[360],"Rapid eye movement sleep behavior disorder (RBD) is important non-movement feature, and also the important risk factor of Parkinson's disease (PD). In our previous work, we found that the movement features and RBD of PD patients improved after taking probiotics. The later was not reported before and the mechanism not clear. To investigate its role and mechanism, we plan to enroll patients of PD-RBD, idiopathic RBD, and healthy control, collect data of multimodal image technology before and after probiotic treatment，including resting state functional MRI，1H-MRS，123I-MIBG; analyze these data with clinical features, including UPDRS -III score, RBD-HK score , as well as the bacteria abundance and level of glutamate，GABA in blood and stool. Then, construct PD mouse model by fecal transplantation of PD patient, give or not give mouse probiotics treatment, and detect the level of glutamate, GABA, and so on, as well as α-synuclein of each brain area of each group, to explore the role and mechanism of probiotics in improving RBD and movement disorder of PD.",[423,424,425,426,427,29],"Parkinson Disease","Movement Disorders","Rapid Eye Movement Sleep Behavior Disorder","Gut Microbiomes","Magnetic Resonance Imaging (MRI)",[29,429,425,430],"Parkinson's disease","Multimodel Magnetic Resonance Imaging","2024-11-29",{"date":433,"type":38},"2024-12-02",{"date":435,"type":38},"2022-09-01",{"date":437,"type":21},"2025-06-30",{"name":439,"class":45},"Beijing Friendship Hospital",{"id":441,"slug":442,"hasResults":11,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":54,"sex":16,"minAge":88,"maxAge":447,"enrollmentInfo":448,"targetDuration":4,"studyType":22,"phases":449,"briefSummary":450,"conditions":451,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":457,"leadSponsor":459,"locationsCount":46},"100570004","changes-in-amino-acid-absorption-after-adding-a-probiotic-to-an-acute-protein-feeding-100570004","NCT06701604","Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding","Comparative Differences of Amino Acid Appearance with Milk Protein Ingestion with and Without Probiotic Supplementation","Inclusion Criteria:\n\n* Participants will be male or female between the ages of 18-35 years;\n* Participants have not been consuming any nutritional supplements for the preceding 6-week period;\n* Participants have not been consuming any ergogenic aids for the preceding 6-week period;\n* Participant has provided written and dated informed consent to participate in the study;\n* Participant is willing and able to comply with the protocol;\n* Participant is apparently healthy and free from disease, as determined by a health history questionnaire;\n\nExclusion Criteria:\n\n* Participant is allergic to any ingredient in the nutritional supplement or placebo;\n* Participant is not pregnant or trying to become pregnant, nor breast feeding;\n* Participant reports any unusual adverse events associated with this study that in consultation with the study investigators or their doctor recommends removal from the study;\n* Participant currently ingests nicotine or has quit within the last 6 months;","35 Years",{"count":119,"type":21},[24],"The purpose of this study is to examine the rate and concentration of amino acid absorption after a three-week pattern of milk protein supplementation with and without the addition of a single strain probiotic.",[452,29],"Amino Acid Absorption","2024-11-20",{"date":455,"type":38},"2024-11-22",{"date":433,"type":21},{"date":458,"type":21},"2026-01-15",{"name":460,"class":160},"The Archer-Daniels-Midland Company"]